Immunogen Inc (IMGN) 7.85 $IMGN
GlycoMimetics Appoints ImmunoGen CEO Daniel Junius to Board of Directors
Business Wire - Mon Mar 21, 8:30AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the appointment of Daniel Junius to its Board of Directors. Mr. Junius is President and Chief Executive Officer and a member of the board of directors of ImmunoGen, Inc., an industry leader in the field of antibody drug conjugates (ADCs). He also serves on the Board of Directors of IDEXX Laboratories, a leading provider of diagnostic and information technology-based products and services for pet healthcare innovation.
IMGN: 7.85 (+0.04), GLYC: 6.04 (+0.03)
8 Biotech Stocks Under $10 Making Big Moves Higher
at The Street - Sun Mar 20, 8:50AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
VSAR: 6.71 (+0.21), DRNA: 4.74 (+0.01), IDRA: 1.99 (+0.04), ITEK: 7.31 (+0.27), MDGN: 4.34 (+0.04), IMGN: 7.85 (+0.04), DNAI: 6.27 (-0.21), NVDQ: 10.41 (unch)
Endometrial Cancer Pipeline Market Research H2 2015 Report
PR Newswire - Wed Mar 02, 8:00PM CST
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INCY: 69.76 (+2.33), IMGN: 7.85 (+0.04), ARQL: 1.63 (+0.06), LLY: 71.12 (-0.05), GSK: 39.56 (+0.19), ONTY: 1.12 (-0.04), MDVN: 42.57 (+3.18), MRK: 53.07 (-0.01), AZN: 28.00 (-0.01), AVEO: 0.95 (unch), GALE: 1.06 (-0.09), PBYI: 36.98 (+0.18), NVS: 73.30 (-0.61), KPTI: 8.42 (+0.05), XLRN: 24.21 (-0.25), EXEL: 4.04 (+0.07)
Shares of IMGN Down 30.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Feb 08, 4:18PM CST
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on January 11th, 2016 at $10.16. In approximately 4 weeks, Immunogen has returned 30.12% as of today's recent price of $7.10.
IMGN: 7.85 (+0.04)
ImmunoGen/Merck Collaborate for Ovarian Cancer Study
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 4:00PM CST
ImmunoGen (IMGN) & Merck tie up to evaluate mirvetuximab soravtansine in combination with Keytruda for ovarian cancer.
MRK: 53.07 (-0.01), IMGN: 7.85 (+0.04), LGND: 102.51 (+1.34), CELG: 100.54 (+0.62)
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfgg5w/relapsed_chronic) has announced the addition of the "Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsed Chronic Lymphocytic Leukemia (CLL) Overview - Therapeutics Development - Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview - Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis - Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies - Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes - Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies - Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes - Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cyclacel Pharmaceuticals, Inc. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Hutchison MediPharma Limited - ImmunoGen, Inc. - Immunomedics, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Innate Pharma SA - Juno Therapeutics Inc. - Karyopharm Therapeutics, Inc. - Les Laboratoires Servier SAS - LFB S.A. - Lymphocyte Activation Technologies, S.A. - MedImmune, LLC - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Ono Pharmaceutical Co., Ltd. - Portola Pharmaceuticals, Inc. - Sanofi - TG Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/rf...ed_chronic
CYCC: 0.43 (+0.02), ABBV: 56.12 (-0.24), INFI: 5.06 (-0.22), JUNO: 36.78 (-0.06), IMMU: 2.47 (-0.01), PTLA: 20.27 (-8.35), EBS: 33.75 (+0.60), INCY: 69.76 (+2.33), IMGN: 7.85 (+0.04), TGTX: 8.26 (-0.08), BMY: 62.52 (+0.18), GILD: 91.32 (+1.24), AZN: 28.00 (-0.01), CELGZ: 1.22 (unch), KPTI: 8.42 (+0.05), NVS: 73.30 (-0.61)
Diffuse Large B-Cell Lymphoma Therapeutics Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwgllc/diffuse_large) has announced the addition of the "Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Diffuse Large B-Cell Lymphoma Overview - Therapeutics Development - Pipeline Products for Diffuse Large B-Cell Lymphoma - Overview - Pipeline Products for Diffuse Large B-Cell Lymphoma - Comparative Analysis - Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies - Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes - Diffuse Large B-Cell Lymphoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Diffuse Large B-Cell Lymphoma - Products under Development by Companies - Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes - Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development - AbbVie Inc. - Acetylon Pharmaceuticals, Inc. - Affimed Therapeutics AG - Amgen Inc. - Aprogen, Inc. - Arrien Pharmaceuticals, LLC - Astellas Pharma Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bayer AG - BeiGene(Beijing) Co.,Ltd - BIND Therapeutics, Inc. - Biocon Limited - Bristol-Myers Squibb Company - Celgene Corporation - Cell>Point, L.L.C. - Cellular Biomedicine Group, Inc. - Constellation Pharmaceuticals, Inc. - CTI BioPharma Corp. - Curis, Inc. - Cyclacel Pharmaceuticals, Inc. - Eisai Co., Ltd. - EpiZyme, Inc. - Erytech Pharma SA - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Hutchison MediPharma Limited - Idera Pharmaceuticals, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovaccine, Inc. - Incyte Corporation - Inflection Biosciences Limited For more information visit http://www.researchandmarkets.com/research/kw...fuse_large
CRIS: 1.50 (+0.03), IMMU: 2.47 (-0.01), INCY: 69.76 (+2.33), IMGN: 7.85 (+0.04), AMGN: 149.24 (+0.48), EPZM: 10.72 (+0.21), BIND: 2.29 (+0.05), GSK: 39.56 (+0.19), BMY: 62.52 (+0.18), CTIC: 0.51 (-0.01), IDRA: 1.99 (+0.04), CYCC: 0.43 (+0.02), GILD: 91.32 (+1.24), AZN: 28.00 (-0.01), ABBV: 56.12 (-0.24), CBMG: 16.72 (+0.79), CELGZ: 1.22 (unch)
ImmunoGen, Inc.'s Earnings Play the Amortization Blues
Brian Orelli, The Motley Fool - Motley Fool - Thu Feb 04, 1:20PM CST
ImmunoGen released earnings for its second fiscal quarter on Friday, but with the lack of any meaningful revenue, it was the update on its pipeline investors should be most interested in. ImmunoGen results: The raw numbers Q2 2016...
IMGN: 7.85 (+0.04), LLY: 71.12 (-0.05), NVS: 73.30 (-0.61)
ImmunoGen and Merck Establish Collaboration for Clinical Evaluation of Mirvetuximab Soravtansine in Combination with Keytruda(R) (pembrolizumab) for the Treatment of Ovarian Cancer
Business Wire - Thu Feb 04, 7:00AM CST
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its ADC technology, and Merck, known as MSD outside the United States and Canada, announced today that they have entered into a clinical research collaboration for the assessment of ImmunoGen's mirvetuximab soravtansine in combination with Merck's anti-PD-1 therapy, Keytruda(R) (pembrolizumab), for the treatment of patients with FRa-positive ovarian cancer.
MRK: 53.07 (-0.01), IMGN: 7.85 (+0.04)
Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, H2 2015
M2 - Thu Feb 04, 4:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rtb7q/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Squamous Cell Carcinoma Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Overview - Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis - Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies - Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies - Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes - Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Altor BioScience Corporation - Amgen Inc. - Ascenta Therapeutics, Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BIND Therapeutics, Inc. - Bionovis SA - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CEL-SCI Corporation - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Eli Lilly and Company - Etubics Corporation - F. Hoffmann-La Roche Ltd. - G&E Herbal Biotechnology Co., Ltd. - Genentech, Inc. - Genexine, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - Gliknik, Inc. - Glycotope GmbH - Hanmi Pharmaceuticals, Co. Ltd. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovative Therapies, Ltd. For more information visit http://www.researchandmarkets.com/research/3r...d_and_neck About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
IMMU: 2.47 (-0.01), CVM: 0.54 (-0.02), CLDX: 3.53 (-0.04), IMGN: 7.85 (+0.04), AMGN: 149.24 (+0.48), LLY: 71.12 (-0.05), BIND: 2.29 (+0.05), GSK: 39.56 (+0.19), BMY: 62.52 (+0.18), AZN: 28.00 (-0.01), AVEO: 0.95 (unch), ABBV: 56.12 (-0.24), XLRN: 24.21 (-0.25)
ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences
Business Wire - Wed Feb 03, 7:00AM CST
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
IMGN: 7.85 (+0.04)
Endometrial Cancer - Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/s66589/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Endometrial Cancer Overview - Therapeutics Development - Pipeline Products for Endometrial Cancer - Overview - Pipeline Products for Endometrial Cancer - Comparative Analysis - Endometrial Cancer - Therapeutics under Development by Companies - Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes - Endometrial Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Endometrial Cancer - Products under Development by Companies - Endometrial Cancer - Products under Investigation by Universities/Institutes - Endometrial Cancer - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acceleron Pharma, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BeiGene(Beijing) Co.,Ltd - Boehringer Ingelheim GmbH - Cellceutix Corporation - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Medivation, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Pharmsynthez - Puma Biotechnology, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/s6...ndometrial
INCY: 69.76 (+2.33), IMGN: 7.85 (+0.04), ARQL: 1.63 (+0.06), LLY: 71.12 (-0.05), GSK: 39.56 (+0.19), ONTY: 1.12 (-0.04), MDVN: 42.57 (+3.18), MRK: 53.07 (-0.01), AZN: 28.00 (-0.01), AVEO: 0.95 (unch), GALE: 1.06 (-0.09), PBYI: 36.98 (+0.18), NVS: 73.30 (-0.61), KPTI: 8.42 (+0.05), XLRN: 24.21 (-0.25), EXEL: 4.04 (+0.07)
Immunogen Down 22.1% Since SmarTrend Downtrend Call (IMGN)
Comtex SmarTrend(R) - Mon Feb 01, 11:35AM CST
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on January 11th, 2016 at $10.16. In approximately 3 weeks, Immunogen has returned 22.14% as of today's recent price of $7.91.
IMGN: 7.85 (+0.04)
ImmunoGen Posts Wider-than-Expected Loss, Retains View
Zacks Equity Research - Zacks Investment Research - Mon Feb 01, 9:10AM CST
ImmunoGen, Inc. (IMGN) reported a loss of 38 cents per share in the second quarter of fiscal 2016.
IMDZ: 10.65 (-0.64), IMGN: 7.85 (+0.04), INFI: 5.06 (-0.22)
ImmunoGen (IMGN) Reports Wider-than-Expected Loss
Zacks Equity Research - Zacks Investment Research - Fri Jan 29, 7:26AM CST
ImmunoGen (IMGN) reported a wider-than-expected loss in the second quarter fiscal 2016.
IMGN: 7.85 (+0.04)
ImmunoGen Reports Second Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update
Business Wire - Fri Jan 29, 5:30AM CST
--Both ImmunoGen's FORWARD I and FORWARD II clinical trials are open for patient enrollment. FORWARD I is designed to support an Accelerated Approval pathway for lead program mirvetuximab soravtansine and FORWARD II assesses this first-in-class folate receptor a (FRa)-targeting antibody-drug conjugate (ADC) in multiple combination regimens.
IMGN: 7.85 (+0.04)
OncBioMune Patents a New Promising Approach to Chemotherapy
ACCESSWIRE - Thu Jan 28, 7:00AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 28, 2016 / Chemotherapy compounds like paclitaxel and docetaxel have been used for years to treat cancer, but the caveat is that they indiscriminately kill both cancerous and normal cells. In order to solve this problem, researchers have tried a number of different approaches. The most common approach has been conjugating anti-cancer agents to antibodies or functional fragments, but even then, there are significant numbers of normal cells affected.
SGEN: 34.68 (+0.09), IMGN: 7.85 (+0.04), PPHM: 0.41 (+0.01), SRNE: 4.98 (+0.04), CELG: 100.54 (+0.62)
ImmunoGen (IMGN) Q2 Earnings Preview: What to Expect?
Zacks Equity Research - Zacks Investment Research - Wed Jan 27, 11:20AM CST
ImmunoGen, Inc. (IMGN) is scheduled to report its second-quarter fiscal 2016 results on Jan 29, before the opening bell.
CYTK: 6.66 (+0.13), GILD: 91.32 (+1.24), IMGN: 7.85 (+0.04)
GlycoMimetics Appoints ImmunoGen CEO Daniel Junius to Board of Directors
Business Wire - Mon Mar 21, 8:30AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the appointment of Daniel Junius to its Board of Directors. Mr. Junius is President and Chief Executive Officer and a member of the board of directors of ImmunoGen, Inc., an industry leader in the field of antibody drug conjugates (ADCs). He also serves on the Board of Directors of IDEXX Laboratories, a leading provider of diagnostic and information technology-based products and services for pet healthcare innovation.
IMGN: 7.85 (+0.04), GLYC: 6.04 (+0.03)
8 Biotech Stocks Under $10 Making Big Moves Higher
at The Street - Sun Mar 20, 8:50AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
VSAR: 6.71 (+0.21), DRNA: 4.74 (+0.01), IDRA: 1.99 (+0.04), ITEK: 7.31 (+0.27), MDGN: 4.34 (+0.04), IMGN: 7.85 (+0.04), DNAI: 6.27 (-0.21), NVDQ: 10.41 (unch)
Endometrial Cancer Pipeline Market Research H2 2015 Report
PR Newswire - Wed Mar 02, 8:00PM CST
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INCY: 69.76 (+2.33), IMGN: 7.85 (+0.04), ARQL: 1.63 (+0.06), LLY: 71.12 (-0.05), GSK: 39.56 (+0.19), ONTY: 1.12 (-0.04), MDVN: 42.57 (+3.18), MRK: 53.07 (-0.01), AZN: 28.00 (-0.01), AVEO: 0.95 (unch), GALE: 1.06 (-0.09), PBYI: 36.98 (+0.18), NVS: 73.30 (-0.61), KPTI: 8.42 (+0.05), XLRN: 24.21 (-0.25), EXEL: 4.04 (+0.07)
Shares of IMGN Down 30.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Feb 08, 4:18PM CST
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on January 11th, 2016 at $10.16. In approximately 4 weeks, Immunogen has returned 30.12% as of today's recent price of $7.10.
IMGN: 7.85 (+0.04)
ImmunoGen/Merck Collaborate for Ovarian Cancer Study
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 4:00PM CST
ImmunoGen (IMGN) & Merck tie up to evaluate mirvetuximab soravtansine in combination with Keytruda for ovarian cancer.
MRK: 53.07 (-0.01), IMGN: 7.85 (+0.04), LGND: 102.51 (+1.34), CELG: 100.54 (+0.62)
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfgg5w/relapsed_chronic) has announced the addition of the "Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsed Chronic Lymphocytic Leukemia (CLL) Overview - Therapeutics Development - Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview - Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis - Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies - Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes - Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies - Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes - Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cyclacel Pharmaceuticals, Inc. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Hutchison MediPharma Limited - ImmunoGen, Inc. - Immunomedics, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Innate Pharma SA - Juno Therapeutics Inc. - Karyopharm Therapeutics, Inc. - Les Laboratoires Servier SAS - LFB S.A. - Lymphocyte Activation Technologies, S.A. - MedImmune, LLC - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Ono Pharmaceutical Co., Ltd. - Portola Pharmaceuticals, Inc. - Sanofi - TG Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/rf...ed_chronic
CYCC: 0.43 (+0.02), ABBV: 56.12 (-0.24), INFI: 5.06 (-0.22), JUNO: 36.78 (-0.06), IMMU: 2.47 (-0.01), PTLA: 20.27 (-8.35), EBS: 33.75 (+0.60), INCY: 69.76 (+2.33), IMGN: 7.85 (+0.04), TGTX: 8.26 (-0.08), BMY: 62.52 (+0.18), GILD: 91.32 (+1.24), AZN: 28.00 (-0.01), CELGZ: 1.22 (unch), KPTI: 8.42 (+0.05), NVS: 73.30 (-0.61)
Diffuse Large B-Cell Lymphoma Therapeutics Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwgllc/diffuse_large) has announced the addition of the "Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Diffuse Large B-Cell Lymphoma Overview - Therapeutics Development - Pipeline Products for Diffuse Large B-Cell Lymphoma - Overview - Pipeline Products for Diffuse Large B-Cell Lymphoma - Comparative Analysis - Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies - Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes - Diffuse Large B-Cell Lymphoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Diffuse Large B-Cell Lymphoma - Products under Development by Companies - Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes - Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development - AbbVie Inc. - Acetylon Pharmaceuticals, Inc. - Affimed Therapeutics AG - Amgen Inc. - Aprogen, Inc. - Arrien Pharmaceuticals, LLC - Astellas Pharma Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bayer AG - BeiGene(Beijing) Co.,Ltd - BIND Therapeutics, Inc. - Biocon Limited - Bristol-Myers Squibb Company - Celgene Corporation - Cell>Point, L.L.C. - Cellular Biomedicine Group, Inc. - Constellation Pharmaceuticals, Inc. - CTI BioPharma Corp. - Curis, Inc. - Cyclacel Pharmaceuticals, Inc. - Eisai Co., Ltd. - EpiZyme, Inc. - Erytech Pharma SA - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Hutchison MediPharma Limited - Idera Pharmaceuticals, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovaccine, Inc. - Incyte Corporation - Inflection Biosciences Limited For more information visit http://www.researchandmarkets.com/research/kw...fuse_large
CRIS: 1.50 (+0.03), IMMU: 2.47 (-0.01), INCY: 69.76 (+2.33), IMGN: 7.85 (+0.04), AMGN: 149.24 (+0.48), EPZM: 10.72 (+0.21), BIND: 2.29 (+0.05), GSK: 39.56 (+0.19), BMY: 62.52 (+0.18), CTIC: 0.51 (-0.01), IDRA: 1.99 (+0.04), CYCC: 0.43 (+0.02), GILD: 91.32 (+1.24), AZN: 28.00 (-0.01), ABBV: 56.12 (-0.24), CBMG: 16.72 (+0.79), CELGZ: 1.22 (unch)
ImmunoGen, Inc.'s Earnings Play the Amortization Blues
Brian Orelli, The Motley Fool - Motley Fool - Thu Feb 04, 1:20PM CST
ImmunoGen released earnings for its second fiscal quarter on Friday, but with the lack of any meaningful revenue, it was the update on its pipeline investors should be most interested in. ImmunoGen results: The raw numbers Q2 2016...
IMGN: 7.85 (+0.04), LLY: 71.12 (-0.05), NVS: 73.30 (-0.61)
ImmunoGen and Merck Establish Collaboration for Clinical Evaluation of Mirvetuximab Soravtansine in Combination with Keytruda(R) (pembrolizumab) for the Treatment of Ovarian Cancer
Business Wire - Thu Feb 04, 7:00AM CST
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its ADC technology, and Merck, known as MSD outside the United States and Canada, announced today that they have entered into a clinical research collaboration for the assessment of ImmunoGen's mirvetuximab soravtansine in combination with Merck's anti-PD-1 therapy, Keytruda(R) (pembrolizumab), for the treatment of patients with FRa-positive ovarian cancer.
MRK: 53.07 (-0.01), IMGN: 7.85 (+0.04)
Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, H2 2015
M2 - Thu Feb 04, 4:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/3rtb7q/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Squamous Cell Carcinoma Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Overview - Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis - Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies - Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies - Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes - Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Altor BioScience Corporation - Amgen Inc. - Ascenta Therapeutics, Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BIND Therapeutics, Inc. - Bionovis SA - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CEL-SCI Corporation - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Eli Lilly and Company - Etubics Corporation - F. Hoffmann-La Roche Ltd. - G&E Herbal Biotechnology Co., Ltd. - Genentech, Inc. - Genexine, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - Gliknik, Inc. - Glycotope GmbH - Hanmi Pharmaceuticals, Co. Ltd. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovative Therapies, Ltd. For more information visit http://www.researchandmarkets.com/research/3r...d_and_neck About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
IMMU: 2.47 (-0.01), CVM: 0.54 (-0.02), CLDX: 3.53 (-0.04), IMGN: 7.85 (+0.04), AMGN: 149.24 (+0.48), LLY: 71.12 (-0.05), BIND: 2.29 (+0.05), GSK: 39.56 (+0.19), BMY: 62.52 (+0.18), AZN: 28.00 (-0.01), AVEO: 0.95 (unch), ABBV: 56.12 (-0.24), XLRN: 24.21 (-0.25)
ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences
Business Wire - Wed Feb 03, 7:00AM CST
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
IMGN: 7.85 (+0.04)
Endometrial Cancer - Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/s66589/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Endometrial Cancer Overview - Therapeutics Development - Pipeline Products for Endometrial Cancer - Overview - Pipeline Products for Endometrial Cancer - Comparative Analysis - Endometrial Cancer - Therapeutics under Development by Companies - Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes - Endometrial Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Endometrial Cancer - Products under Development by Companies - Endometrial Cancer - Products under Investigation by Universities/Institutes - Endometrial Cancer - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acceleron Pharma, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BeiGene(Beijing) Co.,Ltd - Boehringer Ingelheim GmbH - Cellceutix Corporation - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Medivation, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Pharmsynthez - Puma Biotechnology, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/s6...ndometrial
INCY: 69.76 (+2.33), IMGN: 7.85 (+0.04), ARQL: 1.63 (+0.06), LLY: 71.12 (-0.05), GSK: 39.56 (+0.19), ONTY: 1.12 (-0.04), MDVN: 42.57 (+3.18), MRK: 53.07 (-0.01), AZN: 28.00 (-0.01), AVEO: 0.95 (unch), GALE: 1.06 (-0.09), PBYI: 36.98 (+0.18), NVS: 73.30 (-0.61), KPTI: 8.42 (+0.05), XLRN: 24.21 (-0.25), EXEL: 4.04 (+0.07)
Immunogen Down 22.1% Since SmarTrend Downtrend Call (IMGN)
Comtex SmarTrend(R) - Mon Feb 01, 11:35AM CST
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on January 11th, 2016 at $10.16. In approximately 3 weeks, Immunogen has returned 22.14% as of today's recent price of $7.91.
IMGN: 7.85 (+0.04)
ImmunoGen Posts Wider-than-Expected Loss, Retains View
Zacks Equity Research - Zacks Investment Research - Mon Feb 01, 9:10AM CST
ImmunoGen, Inc. (IMGN) reported a loss of 38 cents per share in the second quarter of fiscal 2016.
IMDZ: 10.65 (-0.64), IMGN: 7.85 (+0.04), INFI: 5.06 (-0.22)
ImmunoGen (IMGN) Reports Wider-than-Expected Loss
Zacks Equity Research - Zacks Investment Research - Fri Jan 29, 7:26AM CST
ImmunoGen (IMGN) reported a wider-than-expected loss in the second quarter fiscal 2016.
IMGN: 7.85 (+0.04)
ImmunoGen Reports Second Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update
Business Wire - Fri Jan 29, 5:30AM CST
--Both ImmunoGen's FORWARD I and FORWARD II clinical trials are open for patient enrollment. FORWARD I is designed to support an Accelerated Approval pathway for lead program mirvetuximab soravtansine and FORWARD II assesses this first-in-class folate receptor a (FRa)-targeting antibody-drug conjugate (ADC) in multiple combination regimens.
IMGN: 7.85 (+0.04)
OncBioMune Patents a New Promising Approach to Chemotherapy
ACCESSWIRE - Thu Jan 28, 7:00AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 28, 2016 / Chemotherapy compounds like paclitaxel and docetaxel have been used for years to treat cancer, but the caveat is that they indiscriminately kill both cancerous and normal cells. In order to solve this problem, researchers have tried a number of different approaches. The most common approach has been conjugating anti-cancer agents to antibodies or functional fragments, but even then, there are significant numbers of normal cells affected.
SGEN: 34.68 (+0.09), IMGN: 7.85 (+0.04), PPHM: 0.41 (+0.01), SRNE: 4.98 (+0.04), CELG: 100.54 (+0.62)
ImmunoGen (IMGN) Q2 Earnings Preview: What to Expect?
Zacks Equity Research - Zacks Investment Research - Wed Jan 27, 11:20AM CST
ImmunoGen, Inc. (IMGN) is scheduled to report its second-quarter fiscal 2016 results on Jan 29, before the opening bell.
CYTK: 6.66 (+0.13), GILD: 91.32 (+1.24), IMGN: 7.85 (+0.04)
